Business Description
Aurinia Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA05156V1022
Total Employee Number:
128Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.52 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 0.44 | |||||
Interest Coverage | 29.15 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.46 | |||||
Beneish M-Score | 7.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 29.3 | |||||
3-Year Book Growth Rate | 15.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.55 | |||||
Quick Ratio | 5.01 | |||||
Cash Ratio | 4.38 | |||||
Days Inventory | 547.79 | |||||
Days Sales Outstanding | 49.38 | |||||
Days Payable | 37.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.4 | |||||
Shareholder Yield % | 4.54 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.74 | |||||
Operating Margin % | 41.77 | |||||
Net Margin % | 99.97 | |||||
EBITDA Margin % | 52.77 | |||||
FCF Margin % | 56.25 | |||||
OCF Margin % | 56.31 | |||||
ROE % | 67.77 | |||||
ROA % | 49.53 | |||||
ROIC % | 64.11 | |||||
3-Year ROIIC % | 90.03 | |||||
ROC (Joel Greenblatt) % | 120.46 | |||||
ROCE % | 26.47 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.43 | |||||
Forward PE Ratio | 11.5 | |||||
PE Ratio without NRI | 7.43 | |||||
Price-to-Owner-Earnings | 6.73 | |||||
PS Ratio | 7.42 | |||||
PB Ratio | 3.71 | |||||
Price-to-Tangible-Book | 3.74 | |||||
Price-to-Free-Cash-Flow | 13.28 | |||||
Price-to-Operating-Cash-Flow | 13.25 | |||||
EV-to-EBIT | 12.53 | |||||
EV-to-EBITDA | 10.99 | |||||
EV-to-Revenue | 5.8 | |||||
EV-to-Forward-Revenue | 25.87 | |||||
EV-to-FCF | 10.17 | |||||
Price-to-GF-Value | 1.14 | |||||
Price-to-Projected-FCF | 9.12 | |||||
Price-to-Graham-Number | 1.11 | |||||
| Price-to-Net-Current-Asset-Value | 6.5 | |||||
| Price-to-Net-Cash | 9.51 | |||||
Earnings Yield (Greenblatt) % | 7.98 | |||||
FCF Yield % | 7.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aurinia Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 431.417 | ||
| EPS (TTM) (C$) | 3.165 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -54.59 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (C$) | - | ||
| 20-Day SMA (C$) | 15.41 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (C$) | 15.41 - 15.41 | ||
| Shares Outstanding (Mil) | 128.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurinia Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurinia Pharmaceuticals Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 89 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 88 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | 15.41 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 15.41 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 12:00 | 15.41 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 | 15.41 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 15.41 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:30 | 15.41 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 15.41 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 15.41 (+0.00%) |
Show
Entries
Aurinia Pharmaceuticals Inc Frequently Asked Questions
What is Aurinia Pharmaceuticals Inc(LTS:0UJF)'s stock price today?
The current price of LTS:0UJF is C$15.41. The 52 week high of LTS:0UJF is C$15.41 and 52 week low is C$15.41.
When is next earnings date of Aurinia Pharmaceuticals Inc(LTS:0UJF)?
The next earnings date of Aurinia Pharmaceuticals Inc(LTS:0UJF) is 2026-11-04 Est..
Does Aurinia Pharmaceuticals Inc(LTS:0UJF) pay dividends? If so, how much?
Aurinia Pharmaceuticals Inc(LTS:0UJF) does not pay dividend.
Press Release
Articles on Aurinia Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers